AstraZeneca completes agreement with LEO Pharma



This announcement contains inside information

16 August 2016 07:00


AstraZeneca today announced that it has completed the licensing agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. Tralokinumab is an IL-13 monoclonal antibody that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.

Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115 million for the exclusive, global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications. As AstraZeneca will retain a significant ongoing interest in tralokinumab, the upfront payment, along with all future commercial milestone and royalty payments, will be reported as Externalisation Revenue in the Company's financial statements.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:


Media Enquiries           
Neil Burrows    UK/Global    +44 203 749 5637   
Vanessa Rhodes    UK/Global    +44 203 749 5736   
Karen Birmingham    UK/Global    +44 203 749 5634   
Rob Skelding    UK/Global    +44 203 749 5821   
Jacob Lund    Sweden    +46 8 553 260 20   
Michele Meixell    US    +1 302 885 2677   
Investor Relations
Thomas Kudsk Larsen   +44 203 749 5712 
Craig Marks  Finance, Fixed Income, M&A +44 7881 615 764 
Nick Stone  Respiratory & Autoimmunity +44 203 749 5716 
Henry Wheeler  Oncology  +44 203 749 5797 
Christer Gruvris Infection & Neuroscience +44 203 749 5711
Lindsey Trickett  Cardiovascular & Metabolic   Diseases +1 240 543 7970
Mitchell Chan   Oncology +1 240 477 3771
Toll free +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC


About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links